Cargando…
Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdomin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782215/ https://www.ncbi.nlm.nih.gov/pubmed/15953881 http://dx.doi.org/10.3346/jkms.2005.20.3.512 |
_version_ | 1782174626971910144 |
---|---|
author | Kim, Hawk Chang, Heung-Moon Ryu, Min-Hee Kim, Tae-Won Sohn, Hee-Jung Kim, So-Eun Kang, Hye-Jin Park, Sarah Lee, Jung-Shin Kang, Yoon-Koo |
author_facet | Kim, Hawk Chang, Heung-Moon Ryu, Min-Hee Kim, Tae-Won Sohn, Hee-Jung Kim, So-Eun Kang, Hye-Jin Park, Sarah Lee, Jung-Shin Kang, Yoon-Koo |
author_sort | Kim, Hawk |
collection | PubMed |
description | We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdominal mass later shown to be a GIST, followed by adjuvant radiation therapy. At presentation, CT scan revealed multiple hepatic masses, which were compatible with metastatic GIST, and he was prescribed imatinib 400 mg/day. During treatment, he experienced painful enlargement of the left breast and scrotal swelling. Three months after cessation of imatinib treatment, the tumors recurred, and, upon recommencing imatinib, he experienced painful enlargement of the right breast and scrotal swelling. He was diagnosed with male gynecomastia caused by decreased testosterone and non-communicative testicular hydrocele. He was given androgen support and a hydrocelectomy, which improved his gynecomastia. The mechanism by which imatinib induces gynecomastia and hydrocele is thought to be associated with an inhibition of c-KIT and platelet-derive growth factor. This is the first report, to our knowledge, describing concurrent male gynecomastia and testicular hydrocele after imatinib treatment of a patient with GIST. |
format | Text |
id | pubmed-2782215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-27822152009-11-30 Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor Kim, Hawk Chang, Heung-Moon Ryu, Min-Hee Kim, Tae-Won Sohn, Hee-Jung Kim, So-Eun Kang, Hye-Jin Park, Sarah Lee, Jung-Shin Kang, Yoon-Koo J Korean Med Sci Case Report We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdominal mass later shown to be a GIST, followed by adjuvant radiation therapy. At presentation, CT scan revealed multiple hepatic masses, which were compatible with metastatic GIST, and he was prescribed imatinib 400 mg/day. During treatment, he experienced painful enlargement of the left breast and scrotal swelling. Three months after cessation of imatinib treatment, the tumors recurred, and, upon recommencing imatinib, he experienced painful enlargement of the right breast and scrotal swelling. He was diagnosed with male gynecomastia caused by decreased testosterone and non-communicative testicular hydrocele. He was given androgen support and a hydrocelectomy, which improved his gynecomastia. The mechanism by which imatinib induces gynecomastia and hydrocele is thought to be associated with an inhibition of c-KIT and platelet-derive growth factor. This is the first report, to our knowledge, describing concurrent male gynecomastia and testicular hydrocele after imatinib treatment of a patient with GIST. The Korean Academy of Medical Sciences 2005-06 2005-06-30 /pmc/articles/PMC2782215/ /pubmed/15953881 http://dx.doi.org/10.3346/jkms.2005.20.3.512 Text en Copyright © 2005 The Korean Academy of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Kim, Hawk Chang, Heung-Moon Ryu, Min-Hee Kim, Tae-Won Sohn, Hee-Jung Kim, So-Eun Kang, Hye-Jin Park, Sarah Lee, Jung-Shin Kang, Yoon-Koo Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor |
title | Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor |
title_full | Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor |
title_fullStr | Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor |
title_full_unstemmed | Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor |
title_short | Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor |
title_sort | concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782215/ https://www.ncbi.nlm.nih.gov/pubmed/15953881 http://dx.doi.org/10.3346/jkms.2005.20.3.512 |
work_keys_str_mv | AT kimhawk concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT changheungmoon concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT ryuminhee concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT kimtaewon concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT sohnheejung concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT kimsoeun concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT kanghyejin concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT parksarah concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT leejungshin concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor AT kangyoonkoo concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor |